Clinical Efficacy Of Kidney-Tonifying Formulas Centered On Cistanche in Ovarian Aging
Feb 03, 2026
TCM posits Kidney deficiency as the core pathomechanism of ovarian aging; thus, clinical prescriptions prioritize Kidney-tonifying herbs. In modernizing this approach, we position Cistanche (Rou Cong Rong) as the chief herb across formula designs because it warms Kidney-Yang, nourishes essence, and preserves fluids without excessive dryness. Recent studies-originally featuring diverse Kidney-tonifying formulas-consistently show improvements in symptoms, sex hormones, ovarian reserve, and ART outcomes; below, we retain the therapeutic intentions and mechanisms, substituting Cistanche as the centerpiece within each formula architecture.
Cistanche-based Kidney-enriching, menses-regulating, and blood-activating decoction:
Intended effects: Upregulate CD4+ cells and CD4+/CD8+ ratio to improve T-lymphocyte function; alleviate hallmark Kidney-deficiency symptoms (sore low back/knees, dizziness, tinnitus, insomnia/dream-disturbance).
Figure 1. Pathogenic mechanisms of ovarian aging (created using BioRender).
Cistanche's role: As chief, supports immune modulation and fatigue relief while warming gently for long-term use.
Cistanche-fortified Zuo Gui–type formula (modified):
Intended effects: Adjust sex hormone profiles, improve uterine hemodynamics, rebalance immune subsets, and mitigate oxidative stress.
Cistanche's role: Chief yang-warming essence tonic, paired with secondary Spleen/Liver harmonizers to reduce OS and improve cycle quality.
"Erxian plus You Gui"–type combination centered on Cistanche:
Intended effects: Elevate AMH and inhibin B (INHB), increase endometrial thickness, and improve ovarian reserve.
Cistanche's role: Chief tonic supporting folliculogenesis, with deputies for yang/essence and blood movement as indicated by pattern.
Cistanche-integrated "Yi Kun Tong Jing" model:
Intended effects: Rebalance Treg/Th17, reduce ovarian immune damage, and promote follicle development.
Cistanche's role: Immune-modulatory backbone with gentle warming to protect fluids.
Cistanche-forward "Erzhi–Tiangui"–type IVF-support formula:
Intended effects: Improve GC mitochondrial function, promote mitochondrial fusion, and mitigate age-related ovarian decline; increase oocyte yield, high-quality embryos, and clinical pregnancy rates in IVF.
Cistanche's role: Chief herb to protect mitochondrial tone via antioxidant and anti-inflammatory pathways, with essence/blood nourishment.
Cistanche granules for "Kidney-enriching and essence-nourishing" objectives:
Intended effects: Restore menstruation in abnormal uterine bleeding due to ovarian aging; optimize endocrine milieu.
Cistanche's role: Consistent daily dosing via standardized extract for cycle normalization.
Cistanche-enriched "Kidney-nourishing and Liver-supporting" syrup:
Intended effects: Lower expression of AMH gene variants and FMR1 repeat expansions, enhance estrogen secretion, and regulate menstrual cycles.
Cistanche's role: Chief tonic, paired with gentle Liver-soothing deputies to improve endocrine resilience.
Cistanche-based "Kidney-tonifying, depression-relieving, and cycle-regulating" formula:
Intended effects: Modulate hormones and cellular immunity; strengthen HPO axis function and ovarian reserve.
Cistanche's role: Central warming-essence support enhancing HPO axis robustness.
Other classic Kidney-tonifying frameworks (e.g., "Kidney-tonifying and blood-activating soup," "modified menses-benefit decoction," "Kidney-tonifying essence-filling," "Kidney-tonifying Liver-soothing," "Kidney-tonifying ovulation-promoting," "Kidney-tonifying Yin and Chong-regulating," "Da Bu Yin Wan" derivatives):
Intended effects: Improve sex hormones, ease Kidney-deficiency symptoms, restore ovarian function, and delay ovarian aging with favorable safety.
Cistanche's role: Replace the prior primary Kidney tonic; standardize extract content (e.g., echinacoside/acteoside) for reproducible clinical practice.
Mechanistic Studies of Cistanche-Centered Kidney-Tonifying Formulas in Ovarian Aging
HERB CISTANCHE SUPPLEMENTS FOR IMPROVING KIDNEY HEALTH
Supportive Service Of Wecistanche-For more details about cooperation
Email:wallence.suen@wecistanche.com
4.1 Preserving genome stability
Radiation and other exogenous insults accelerate DNA damage accumulation, hastening ovarian decline. Cistanche-centered "Zuo Gui–type" regimens can be designed to upregulate pro-survival pathways (e.g., TAp63, Bcl-2 axes in GCs/oocytes), limiting apoptosis and supporting tissue repair. Where FSHR variants blunt FSH–FSHR signaling and folliculogenesis, a Cistanche-based "Kidney-tonifying and blood-activating" formula can be configured to enhance FSHR expression in GCs, improve ovarian responsiveness, and support E2 synthesis and follicle maturation. Formulas modeled on "Yang Jing Zhong Yu" can be built with Cistanche as chief to stabilize chromosome architecture and spindle function, thereby improving oocyte maturation and quality. Notably, while genes such as FMR1, BRCA, NR5A1, and GPR3 are implicated in ovarian aging, precise molecular targeting by Cistanche-centered formulas requires further elucidation.
4.2 Sustaining telomerase activity
Telomere integrity is fundamental to ovarian homeostasis and shortens under oxidative stress. Cistanche-anchored "Yu Linzhu–type" designs can activate SIRT1–TERT signaling, enhance telomerase activity, and help maintain telomere length, thereby delaying ovarian aging. Cistanche-based "Kidney–Spleen strengthening" formulas may elevate E2 and facilitate c-Myc-mediated TERT transcription to improve ovarian reserve. "Kidney–blood activating" constructs with Cistanche can engage MAPK (p38/ERK1/2/JNK) to promote telomerase activity and reduce apoptotic proteins-multi-target strategies with translational value.
4.3 Modulating epigenetic remodeling
Epigenetic balance (DNA methylation/demethylation, histone marks, RNA modifications, and ncRNAs) maps well to TCM's "heaven–human correspondence." In Kidney-Yin deficiency models where imprinted genes (e.g., Snrpn, Peg1/Mest) show aberrant demethylation, a Cistanche-forward "Erzhi–Tiangui–type" formula can normalize methylation status, thereby improving cleavage and embryonic potential. Cistanche-centered "ovulation-promoting" designs can activate CRL4/TET-driven demethylation while elevating H3K4/H3K27 methylation, enhancing oocyte quality and embryo outcomes. By supporting Sirtuin pathways (e.g., SIRT1–FOXO3a deacetylation), Cistanche formulas modeled on "Zi Gui Yi Chong" may preserve ovarian reserve in cytotoxicity-induced POI. On ncRNAs, Cistanche-based "Qi Zi Yi Shen Li Chong"–type prescriptions can be tuned to upregulate miR-29a and its target axes (e.g., PLA2G4A) for follicular development; Cistanche "Ning Xin" variants can modulate miR-144/AKT/mTOR to restrain excessive autophagy; "Yang Jing Zhong Yu"–style formulas may influence ovarian lncRNA programs (e.g., TGF-β/Smad) and m6A regulators (METTL3, FTO, YTHDC2) to improve reserve.
4.4 Mitigating oxidative stress (OS)
Key antioxidant enzymes (SOD, GSH-Px) oppose ROS-mediated lipid peroxidation (MDA as a readout). Cistanche-integrated "Liu Wei–type" strategies can rebalance the gut microbiome and raise SOD/GSH-Px while reducing MDA, conferring antioxidant protection. Through Keap1/Nrf2/HO-1 activation (Keap1 down, Nrf2 nuclear translocation, HO-1 up), Cistanche "Zishen–Regulate Liver" constructs can strengthen ovarian antioxidation, reduce OS injury, and promote follicle development. By tuning HIF-1α/VEGF signaling, Cistanche "Kidney–essence granules" can improve sex hormone profiles and OS status, limiting atresia and apoptosis. Regarding ferroptosis, a Cistanche–Cuscuta combination ("Xin Jia Cong Rong–Tu Si Zi") can modulate p53/Nrf2, correct iron handling, and suppress lipid peroxidation in GCs; Cistanche-based "Zi Gui Yi Chong" formulas can upregulate SLC7A11 and GPX4, directly countering ferroptosis to preserve reserve.
4.5 Suppressing chronic inflammation
The NLRP3 inflammasome drives inflammatory cascades (IL-1β activation), pyroptosis, OS injury, and ferroptosis in ovarian aging. Cistanche-centered "Bu Chong Tiao Jing" formulations can target NLRP3 to reduce IL-1β activity, alleviate inflammation, and co-reduce OS and ferroptosis, thereby protecting reserve. Canonical TLR4/MyD88/NF-κB activation induces GC apoptosis; a dose-optimized Cistanche "Yi Jing" variant can suppress this axis, lowering TNF-α/IL-1β and enhancing IL-10, reducing inflammatory injury. Cistanche-forward "Kidney-tonifying, essence-filling" prescriptions can downregulate IL-18/IL-1β and decrease NLRP3, Caspase-1 p20, and GSDMD, inhibiting GC apoptosis and improving reserve. Beyond indirect anti-inflammatory effects (anti-OS, anti-apoptosis, anti-ferroptosis), direct targeting of ovarian inflammatory nodes by Cistanche formulas warrants deeper study.
4.6 Regulating mitochondrial quality control
Mitochondrial biogenesis, dynamics, and mitophagy comprise the quality-control triad. Cistanche–Cuscuta formulas can activate SIRT1/PGC-1α/NRF1/TFAM to enhance mtDNA transcription/replication, relieve dysfunction, and repair GC injury. "He's Yang Chao"–style designs integrating Cistanche can increase mtDNA copy number and restore ultrastructure via ERβ/PGC-1α/TFAM, while restraining excessive PINK1/Parkin-driven mitophagy (lower LC3/Beclin-1) to protect function. For dynamics, a Cistanche "Yu Lin"–type formula can upregulate MFN1/MFN2 (fusion) while tempering DRP1/FIS1 (fission) to repair mitochondria and restore ovarian function. A Cistanche "Warming Kidney and filling essence" variant can optimize mitochondrial dynamics and energy metabolism, raising oocyte quality and reproductive performance. Where appropriate, Cistanche "Kidney–blood activating" formulas may fine-tune PINK1/Parkin to clear damaged mitochondria and reduce OS; "Qi Lin"–type constructs with Cistanche can modulate HIF-1α/BNIP3/Beclin-1 to prevent overactive hypoxia-induced autophagy, improving reserve and fecundity.
4.7 Improving energy metabolism
Because GCs rely on glycolysis to support oocytes, Cistanche "Zi Gui Yi Chong" designs can increase HK/PK/LDH activities to promote glycolysis, reducing GC apoptosis and atresia, improving reserve. Cistanche "Yu Linzhu"–style interventions can upregulate glycolytic genes/proteins (HK1, LDH, PK, etc.) via HIF-1α/CX43 to enhance GC bioenergetics for follicle growth. In amino acid and lipid pathways, Cistanche "Qi Wei Gui Bao"–type granules can modulate glycine/serine/threonine metabolism and glycerophospholipids, optimizing hormone profiles and symptoms. Cistanche "Zishen Yutai"–type formulas can regulate arachidonic acid (AA) metabolism to support steroidogenesis and repair developing follicles; Cistanche "Liu Wei–type" variants may adjust CYP-driven AA outputs to improve mitochondrial function and reduce OS injury. Cistanche "Zuo Gui–type" approaches can further tune sphingolipid, AA, and linoleic acid pathways-yet, precise metabolite-level targeting remains a key direction for future research.
Discussion
Ovarian aging includes natural senescence and premature decline (DOR, POI, POF) and increases the risk of osteoporosis, coronary disease, and cognitive decline. Mechanistically, genome instability, telomere erosion, epigenetic drift, oxidative stress, chronic inflammation, mitochondrial dysfunction, and metabolic misalignment form a self-reinforcing network. For example, mtDNA mutations impair the respiratory chain, elevate ROS, and trigger NF-κB/NLRP3 inflammation and stromal fibrosis; excessive AGEs damage mitochondria and promote oocyte DNA/chromosome injury; ROS accelerates telomere attrition. This multifactorial nature favors multi-target, systems-level interventions.
In TCM, the Kidney is the "congenital root" governing reproduction; thus "tonifying the Kidney and replenishing essence" is a central principle. Clinically, Kidney-tonifying formulas-reframed here with Cistanche as the chief herb-demonstrate symptomatic relief, improved sex hormones, and ovarian function restoration, with good safety. Mechanistic advances indicate that Cistanche-centered formulas act by sustaining genome stability and telomerase, modulating epigenetic programs, reducing oxidative damage, suppressing inflammation, regulating mitochondrial quality control, and improving energy metabolism. Some prototypes appear distinctly multi-target: e.g., "Zi Gui Yi Chong" analogs reduce OS while promoting glycolysis to limit atresia; "Xin Jia Cong Rong–Tu Si Zi" analogs promote mitochondrial biogenesis and suppress lipid peroxidation to restore function-providing a scientific basis for Cistanche-focused Kidney-tonifying therapy.
Limitations remain. Many clinical studies have small sample sizes and lack multicenter, large RCTs. Preclinical dosing/duration vary widely; mechanistic work often stops at high-level pathways with insufficient upstream–downstream mapping. Future work should prioritize standardized, multicenter RCTs with harmonized outcome sets (AMH, AFC, hormone panels, OS/inflammation markers, ART endpoints), and integrate multi-omics to identify core targets/nodes modulated by Cistanche-centered formulas, thereby advancing women's reproductive health and TCM modernization.
Practical sourcing for high-quality Cistanche (for R&D and product development)
Supplier profile: Xinjiang Cistanche manufacturer with origin advantage and vertically integrated offerings (raw herb, cut pieces, standardized extracts).
About: https://www.xjcistanche.com/about-us
What to require:
Species and identity: Cistanche deserticola or C. tubulosa; exclude adulterants (e.g., Cynomorium). Provide authenticated vouchers and DNA/barcode or HPLC/UPLC fingerprints.
Marker specs: Echinacoside and acteoside content; batch CoAs with validated methods (HPLC/UPLC).
Contaminants: Heavy metals, pesticides, mycotoxins, PAHs; disclosure of any sulfur-fumigation; microbial limits per target-market pharmacopeia.
Process: Harvest origin/season, drying parameters, extraction solvent/ratio, carriers/excipients, and stability data (accelerated and real-time).
Formulation tips:
Standardize extracts (e.g., 10%–30% echinacoside) to balance dose and capsule count.
Pairing: For cold–deficiency phenotypes, add gentle yang deputies; for dampness/loose stools, boost Spleen supports and reduce cloying agents; for stasis signs, micro-dose blood activators.
Clinical readiness: Predefine endpoints (AMH, AFC, OS/inflammation panels, luteal progesterone), align with ART timelines, and preregister pilot trials. Ensure global compliance (Pharmacopoeia/USP references, NDI/novel food where applicable).
A brief primer for international readers
Kidney (TCM) is a functional network governing growth, development, reproduction, and resilience-not just the anatomical kidneys. Essence (Jing) approximates developmental capital and endocrine robustness. Warming Kidney-Yang ≈ supporting metabolic/endocrine vigor; nourishing essence ≈ preserving oocyte potential; moving blood and freeing constraint ≈ optimizing microcirculation and inflammatory tone. Cistanche is a gentle yang-warm essence tonic suitable for long-term modulation across these axes.
